Schizophrenia affects an estimated 3.2 million adults in the United States, which represents about 1.2% of the adult population. A core and disabling feature of schizophrenia is cognitive impairment, affecting abilities such as memory, attention, processing speed, and executive function. This condition, known as Cognitive Impairment Associated with Schizophrenia (CIAS), impacts the patients' ability to work, maintain social relationships, and live independently. Currently, there are no approved treatments for CIAS.
The stock we are bringing to your attention today is that of Alto Neuroscience Inc. (ANRO), a clinical-stage biopharmaceutical company, developing a drug for cognitive impairment associated with schizophrenia.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.